Comparative Pharmacology
Head-to-head clinical analysis: RAYOS versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAYOS versus UCERIS.
RAYOS vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category C
Category C
Corticosteroid
Corticosteroid